Quality of Life Changes in Early-Onset Multiple Sclerosis: A 4-Year Follow-Up Study
- PMID: 36079156
- PMCID: PMC9456623
- DOI: 10.3390/jcm11175226
Quality of Life Changes in Early-Onset Multiple Sclerosis: A 4-Year Follow-Up Study
Abstract
This study investigates longitudinal changes in health-related quality of life (HRQoL) in early-onset multiple sclerosis (MS) patients and explores the impact of disease activity (relapses) on such changes. People with MS (PwMS) onset between 12 and 25 years of age were followed longitudinally. At baseline and at year 4, patients were asked to fill the Paediatric Quality of life inventory (PedsQL). Demographic and clinical features were collected at both time points. Longitudinal within-group comparison of HRQoL total score and sub-scores was performed via paired samples t-test. The effect of relapses on the HRQoL changes over time was explored via linear mixed-effects analysis. No longitudinal changes were observed in the overall PedsQL score, nor in the physical, school and psychological functioning. An increase in the social functioning subscale (p < 0.001) and a decrease in the emotional subscale (p = 0.006) were observed. The change in social functioning, but not the one in the emotional subscale, was affected by the occurrence of relapses (p = 0.044). In conclusion, stimulating the patients to accept their emotional responses to health-related limitations, while preserving their social and relational resources seems key to the preservation of an adequate QoL over time in juvenile-onset MS.
Keywords: early-onset; multiple sclerosis; quality of life.
Conflict of interest statement
L.R. has nothing to disclose. M.P. has received travel grants from Novartis. A.C. (Antonio Carotenuto) has received research grants from ALMIRALL and honoraria from Novartis, Merck and Biogen. P.D., K.P., F.D., F.L. and A.L.S. have nothing to disclose. M.M. has received research grants from ECTRIMS-MAGNIMS, the UK MS Society and Merck, honoraria from Biogen, Merck, Novartis and Roche and consulting fees from Veterans Evaluation Services. L.L. has nothing to disclose. C.I. has nothing to disclose. G.S. has nothing to disclose. N.M.M. and A.C. (Alessandro Chiodi) have nothing to disclose. V.B.M. has received personal compensation for speaking or consultancy from Biogen, Teva, Genzyme, Merck, Novartis and Almirall. R.L. has received personal compensation for speaking or consultancy from Biogen, Teva, Gen-zyme, Merck, Novartis and Almirall.
Figures
References
-
- Miller D.M., Rudick R.A., Baier M., Cutter G., Doughtery D.S., Weinstock-Guttman B., Mass M.K., Fisher E., Simonian N. Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis. Mult. Scler. J. 2003;9:1–5. doi: 10.1191/1352458503ms888oa. - DOI - PubMed
LinkOut - more resources
Full Text Sources